secwatch.observer — SEC 8-K summary
======================================

Issuer:     PROTHENA CORP PUBLIC LTD CO (PRTA)
CIK:        0001559053
Form:       8-K
Filed at:   2026-02-19T23:59:59+00:00
Accession:  0001559053-26-000003
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Prothena posts Q4 2025 net loss $21.6M; full-year loss $244.1M; 2026 cash burn guide $50-55M
--------------------------------------------------------------------------------

- Net loss $21.6M ($0.40 EPS) in Q4 vs $58.0M loss ($1.08 EPS) in Q4 2024; full-year loss $244.1M ($4.53 EPS).
- Total revenue $21K in Q4 vs $2.1M a year ago; full-year revenue $9.7M vs $135.2M in 2024.
- Cash & restricted cash $308.4M at Dec 31, 2025; no debt; shares outstanding ~53.8M.
- 2026 guidance: net cash used in ops $50-55M; year-end cash ~$255M; excludes up to $105M milestones.
- Partners Roche, Novo Nordisk, BMS initiated Phase 3 trials for prasinezumab, coramitug, and BMS-986446.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1559053/000155905326000003/0001559053-26-000003-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1559053/000155905326000003/prta-20260219.htm
  HTML page:      https://secwatch.observer/filing/0001559053-26-000003

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer